Biogen’s Latest Leadership Change Hints At Immunology Ambitions
Research Hire Part Of Ongoing Executive Shuffle
New head of research Jane Grogan comes to Biogen from start-ups Graphite Bio and ArsenalBio, and previously held leadership positions in autoimmune and oncology R&D at Genentech.
You may also be interested in...
The company announced a new $1bn cost savings program that will result in 1,000 job cuts; $300m of the savings will be reinvested in new drug launches and R&D.
The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.
Christopher Viehbacher, former Sanofi CEO and current managing partner at Gurnet Capital, will be charged with returning Biogen to growth with a second big Alzheimer’s launch looming.